Aptevo Therapeutics Files 8-K for Bylaw Amendments
Ticker: APVO · Form: 8-K · Filed: May 23, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, filing
Related Tickers: APVO
TL;DR
APVO filed an 8-K on 5/23 for bylaw changes & financials.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on May 23, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware with its principal executive offices in Seattle, Washington, operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates potential changes in Aptevo's corporate governance or financial reporting structure, which could impact how the company operates and is regulated.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Numbers
- 001-37746 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1567056 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- May 23, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Seattle, Washington (location) — Principal Executive Offices
- 206-838-0500 (phone_number) — Business Phone
FAQ
What specific amendments were made to Aptevo Therapeutics Inc.'s articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What is the significance of the 'Financial Statements and Exhibits' item reported in this 8-K?
This item signifies that financial statements and related exhibits are being filed with the SEC as part of this report, which could include updated financial performance data.
When was Aptevo Therapeutics Inc. incorporated, and in which state?
Aptevo Therapeutics Inc. was incorporated in Delaware.
What is the primary business of Aptevo Therapeutics Inc.?
Aptevo Therapeutics Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].
Where are Aptevo Therapeutics Inc.'s principal executive offices located?
The principal executive offices of Aptevo Therapeutics Inc. are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding Aptevo Therapeutics Inc. (APVO).